MedTrace Logo

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

NCT02126579 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any changes in your immune system.

Conditions

Interventions

BIOLOGICAL

Peptide Vaccine (LPV7) + Tetanus peptide

1.5 mL administered half intradermally and half subcutaneously.

OTHER

PolyICLC

1 mL administered half intradermally and half subcutaneously

OTHER

Resiquimod

500 mg applied to vaccine site after vaccine administration

OTHER

IFA

2 mL administered half intradermally and half subcutaneously

Sponsors & Collaborators

  • University of Virginia

    collaborator OTHER

  • Craig L Slingluff, Jr

    lead OTHER

Principal Investigators

  • Craig L Slingluff, Jr., M.D. · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-01
Primary Completion
2019-11-20
Completion
2021-05-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02126579 on ClinicalTrials.gov